T4 Release Research Articles

In Vitro, Ex Vivo, and In Vivo Determination of Thyroid Hormone Modulating Activity of Benzothiazoles.

As invitro assays are increasingly used to screen chemicals for their potential to produce endocrine disrupting adverse effects, it is important to understand their predictive capacity. The potential for a set of 6 benzothiazoles to affect endpoints related to thyroid hormone synthesis inhibition were assessed using invitro, ex vivo, and invivo assays. Inhibition of thyroid peroxidase (TPO) derived from pig thyroid glands was determined for benzothiazole (BTZ), 2-mercaptobenzothiazole (MBT), 5-chloro-2-mercaptobenzothiazole (CMBT), 2-aminobenzothiazole (ABT), 2-hydroxybenzothiazole (HBT), and 2-methylthiobenzothiazole (MTBT). Their rank order potency for TPO inhibition was MBT=CMBT>ABT>BTZ, whereas HBT and MTBT exhibited no inhibitory activity. The benzothiazoles were tested further in a Xenopus laevis thyroid gland explant culture assay in which inhibition of thyroxine (T4) release was the measured endpoint. In this assay all 6 benzothiazoles inhibited T4 release. The activity of the benzothiazoles for disrupting thyroid hormone activity was verified invivo using X. laevis tadpoles in a 7-day assay. The 2 most potent chemicals for TPO inhibition, MBT and CMBT, produced responses invivo indicative of T4 synthesis inhibition including induction of sodium iodide symporter mRNA and decreases in glandular and circulating thyroid hormones. The capability to measure thyroid hormone levels in the glands and blood by ultrahigh performance LC-MS/MS methods optimized for small tissue samples was critical for effects interpretation. These results indicate that inhibition of TPO activity invitro was a good indicator of a chemical's potential for thyroid hormone disruption invivo and may be useful for prioritizing chemicals for further investigation.

The allosteric modulation of thyroxine-binding globulin affinity is entropy driven

BackgroundThyroxine-binding globulin (TBG) is a non-inhibitory member of the serpin family of proteins whose main structural element is the reactive center loop (RCL), that, upon cleavage by proteases, is inserted into the protein core adopting a β-strand conformation (stressed to relaxed transition, S-to-R). After S-to-R transition thyroxine (T4) affinity decreases. However, crystallographic studies in the presence or absence of the hormone in different states are unable to show significant differences in the structure and interactions of the binding site. Experimental results also suggest the existence of several S states (differing in the number of inserted RCL residues), associated with a differential affinity. MethodsTo shed light into the molecular basis that regulates T4 affinity according to the degree of RCL insertion in TBG, we performed extended molecular dynamics simulations combined with several thermodynamic analysis of the T4 binding to TBG in three different S states, and in the R state. ResultsOur results show that, despite T4 binding in the protein by similar interactions in all states, a good correlation between the degree of RCL insertion and the binding affinity, driven by a change in TBG conformational entropy, was observed. ConclusionTBG allosteric regulation is entropy driven. The presence of multiple S states may allow more efficient T4 release due to protease activity. General significanceThe presented results are clear examples of how computer simulation methods can reveal the thermodynamic basis of allosteric effects, and provide a general framework for understanding serpin allosteric affinity regulation.

Sodium selenite increases the transcript levels of iodothyronine deiodinases I and II in ovine and bovine fetal thyrocytes in vitro

Selenium is essential for thyroid hormone homeostasis. Selenium is co-translationally incorporated into the protein backbone of 5′ deiodinase enzymes, which are responsible for the intra- and extra-thyroidal activation of thyroid hormones. The objective of this study was to evaluate the effects of sodium selenite on the transcript levels of type I (DIO1) and II (DIO2) deiodinases in the primary culture of ovine and bovine fetal thyroid. By culture of fetal thyrocytes in the presence or absence of sodium selenite, and quantification of DIO1 and DIO2 transcripts using real-time reverse transcription polymerase chain reaction (RT-qPCR), we found that sodium selenite is able to increase the abundance of transcripts for DIO1 and DIO2 genes. We also found that cultured thyrocytes in the presence of sodium selenite compared to control cultured thyrocytes release more T3 into the culture medium. This indicates that in the presence of sodium selenite higher levels of DIO1 and DIO2 enzymes are produced, which are able to convert T4 to T3. In conclusion, we have shown that sodium selenite is increasing the abundance of DIO1 and DIO2 transcripts and increasing the production and release of T3 from cultured fetal thyrocytes. This finding emphasizes the role of selenium in transcriptional and expression processes during development and suggests that selenium deficiency during pregnancy in sheep and cattle may lead to the lower levels of DIO1 and DIO2 transcription in fetal thyroid, and thus, lower level of thyroidal T3 release into the fetal serum.

The -258A/G (SNP rs12885300) polymorphism of the human type 2 deiodinase gene is associated with a shift in the pattern of secretion of thyroid hormones following a TRH-induced acute rise in TSH

Type 2 deiodinase gene (DIO2) polymorphisms have been associated with changes in pituitary-thyroid axis homeostasis. The -258A/G (SNP rs12885300) polymorphism has been associated with increased enzymatic activity, but data are conflicting. To characterize the effects of -258A/G polymorphism on intrathyroidal thyroxine (T(4)) to triiodothyronine (T(3)) conversion and thyroid hormone (TH) secretion pattern, we studied the effects of acute, TRH-mediated, TSH stimulation of the thyroid gland. Retrospective analysis. The TH secretion in response to 500 μg i.v. TRH injection was studied in 45 healthy volunteers. Twenty-six subjects (16 females and ten males, 32.8 ± 10.4 years) were homozygous for the ancestral (-258A/A) allele and 19 (11 females and eight males, 31.1 ± 10.9 years) were carriers of the (-258G/x) variant. While no differences in the peak TSH and T(3) levels were observed, carriers of the -258G/x allele showed a blunted rise in free T(4) (FT(4); P<0.01). The -258G/x92Thr/Thr haplotype, compared with the other groups, had lower TSH values at 60 min (P<0.03). No differences were observed between genotypes in baseline TH levels. The -258G/x DIO2 polymorphism variant is associated with a decreased rate of acute TSH-stimulated FT(4) secretion with a normal T(3) release from the thyroid gland consistent with a shift in the reaction equilibrium toward the product. These data indicate that the -258G DIO2 polymorphism causes changes in the pattern of hormone secretion. These findings are a proof of concept that common polymorphisms in DIO2 can subtly affect the circulating levels of TH and might modulate the TH homeostasis.

Thyroid storm during induction of anesthesia

Thyroid storm during induction of anesthesia

A Pathway Approach to Predicting Thyroid Hormone Disrupting Activity of Chemicals Using In Vitro, Ex Vivo and In Vivo Assays

Event Abstract Back to Event A Pathway Approach to Predicting Thyroid Hormone Disrupting Activity of Chemicals Using In Vitro, Ex Vivo and In Vivo Assays Michael Hornung1*, Sigmund J. Degitz1, Joseph E. Tietge1, Joseph J. Korte1, Jonathan T. Haselman1, Patricia A. Kosian1, Annelie J. Lindberg-Livingston2 and Emily M. Burgess2 1 US EPA, Mid-Continent Ecology Division, United States 2 Student Services Contractor, United States The potential for commercial and industrial chemicals that may be released into the environment to have endocrine disrupting activity is of concern for human health and wildlife. Most initial endocrine disruptor research has focused on estrogen- or androgen-mediated pathways. In contrast, research on the capacity of chemicals to alter thyroid hormone (TH) pathways has been relatively limited. Disruption of thyroid hormone function may occur via multiple pathways including altered TH receptor binding, increased TH metabolism and elimination, and altered TH synthesis. The aim of this research was to assess chemicals for their ability to affect TH synthesis and downstream pathways using assays that span biological levels of organization from in vitro to in vivo. The activity of TPO, which is the enzyme that catalyzes iodination and coupling of tyrosines to produce TH, was measured in vitro using porcine thyroid microsomes. Inhibition of TPO activity was determined initially for the two model TH synthesis inhibitors, methimazole and propylthiouracil (PTU). Other chemicals were selected for testing based upon their structural similarity to methimazole or other known TPO inhibitors. Most chemicals were inactive for inhibiting TPO activity; however, mercaptobenzothiazole (MBT) was found to inhibit TPO activity, with an IC50 near 1 µM. This chemical was tested further in a Xenopus laevis thyroid gland explant culture assay in which inhibition of thyroxine (T4) release was the measured endpoint. MBT inhibited T4 release from thyroid glands at non-cytotoxic concentrations and with potency similar to methimazole. The activity of MBT for disrupting thyroid hormone production was confirmed in vivo in X. laevis tadpoles where it produced effects consistent with TH synthesis inhibition. Using a suite of assays across levels of biological organization is a promising approach to identifying endocrine disrupting chemicals. This abstract does not necessarily reflect U.S. EPA policy. Keywords: amphibian, endocrine disruption, thyroid, Xenopus Conference: ISAREN 2011: 7th International Symposium on Amphibian and Reptilian Endocrinology and Neurobiology, Ann Arbor, United States, 11 Jul - 13 Jul, 2011. Presentation Type: Invited Symposium Topic: Endocrine disruption Citation: Hornung M, Degitz SJ, Tietge JE, Korte JJ, Haselman JT, Kosian PA, Lindberg-Livingston AJ and Burgess EM (2011). A Pathway Approach to Predicting Thyroid Hormone Disrupting Activity of Chemicals Using In Vitro, Ex Vivo and In Vivo Assays. Front. Endocrinol. Conference Abstract: ISAREN 2011: 7th International Symposium on Amphibian and Reptilian Endocrinology and Neurobiology. doi: 10.3389/conf.fendo.2011.03.00020 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 22 Jul 2011; Published Online: 09 Aug 2011. * Correspondence: Dr. Michael Hornung, US EPA, Mid-Continent Ecology Division, Duluth, MN, 55804, United States, hornung.michael@epa.gov Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Michael Hornung Sigmund J Degitz Joseph E Tietge Joseph J Korte Jonathan T Haselman Patricia A Kosian Annelie J Lindberg-Livingston Emily M Burgess Google Michael Hornung Sigmund J Degitz Joseph E Tietge Joseph J Korte Jonathan T Haselman Patricia A Kosian Annelie J Lindberg-Livingston Emily M Burgess Google Scholar Michael Hornung Sigmund J Degitz Joseph E Tietge Joseph J Korte Jonathan T Haselman Patricia A Kosian Annelie J Lindberg-Livingston Emily M Burgess PubMed Michael Hornung Sigmund J Degitz Joseph E Tietge Joseph J Korte Jonathan T Haselman Patricia A Kosian Annelie J Lindberg-Livingston Emily M Burgess Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.

The Thr92Ala 5′ Type 2 Deiodinase Gene Polymorphism Is Associated with a Delayed Triiodothyronine Secretion in Response to the Thyrotropin-Releasing Hormone–Stimulation Test: A Pharmacogenomic Study

The common Thr92Ala D2 polymorphism has been associated with changes in pituitary-thyroid axis homeostasis, but published results are conflicting. To investigate the effects of the Thr92Ala polymorphism on intrathyroidal thyroxine (T4) to triiodothyronine (T3) conversion, we designed prospective pharmacogenomic intervention aimed to detect differences in T3 levels after thyrotropin (TSH)-releasing hormone (TRH)-mediated TSH stimulation of the thyroid gland. Eighty-three healthy volunteers were screened and genotyped for the Thr92Ala polymorphism. Fifteen volunteers of each genotype (Thr/Thr, Thr/Ala, and Ala/Ala) underwent a 500 mcg intravenous TRH stimulation test with serial measurements of serum total T3 (TT3), free T4, and TSH over 180 minutes. No differences in baseline thyroid hormone levels were seen among the study groups. Compared to the Thr/Thr group, the Ala/Ala group showed a significantly lower TRH-stimulated increase in serum TT3 at 60 minutes (12.07 ± 2.67 vs. 21.07 ± 2.86 ng/dL, p = 0.029). Thr/Ala subjects showed an intermediate response. Compared to Thr/Thr subjects, the Ala/Ala group showed a blunted rate of rise in serum TT3 as measured by mean time to 50% maximum delta serum TT3 (88.42 ± 6.84 vs. 69.56 ± 6.06 minutes, p = 0.028). Subjects attained similar maximal (180 minutes) TRH-stimulated TT3 levels. TRH-stimulated TSH and free T4 levels were not significantly different among the three genotype groups. The commonly occurring Thr92Ala D2 variant is associated with a decreased rate of acute TSH-stimulated T3 release from the thyroid consistent with a decrease in intrathyroidal deiodination. These data provide a proof of concept that the Thr92Ala polymorphism is associated with subtle changes in thyroid hormone homeostasis.

Effects of fence height on total and free iodothyronine changes in horses after experimental show jumping sessions

Involvement of thyroid function on performance warrants further investigation as limited data exists on the effects of showjumping on the dynamics of total and free iodothyronines. To investigate the response of circulating total and free iodothyronines in horses to experimental showjumping sessions and compare with the effects normally induced by competition and determine if fence height has any effect. Using a randomised crossover study design 6 trained horses were studied during experimental showjumping sessions over 10 fences of different height: 1.00 m (Session 1), 1.10 m (Session 2), 1.20 m (Session 3). Hormone levels were recorded before, after warm-up, 5 and 30 min post exercise. T(3), T(4), fT(3), fT(4) concentrations were analysed by ELISA/competition using streptavidin technology. RM-ANOVA was applied to test for any differences in basal and warm-up values of different sessions. Two way RM-ANOVA was applied to test for any effects of interaction between fence height and time. The differences between individual means over time were assessed using a post hoc multiple comparison test (Bonferroni). Basal T(4) changes over the sessions (P < 0.05) were recorded. After warm-up, T(4) concentration results were lower than basal in Session 1 (P < 0.05). Higher than basal values were recorded 30 min post exercise for T(3) (P < 0.001), T(4) and fT(4) (P < 0.01) in Session 2 and for T(4) (P < 0.05) and fT(4) (P < 0.01) in Session 3. The interaction fence height/time results were significant on T(3) (P < 0.03) and fT(4) (P < 0.03); sampling time on T(3) (P < 0.0007), T(4) (P < 0.001) and fT(4) (P < 0.002) post exercise changes. Showjumping over the highest fences induced a release of T(3) from skeletal muscle, probably due to 5'-desiodase activity and increase of fT(4), due to thyroid stimulation and/or changes in capacity to bind iodothyronines.

Resistance to Thyroid Hormone Due to a Novel Thyroid Hormone Receptor Mutant in a Patient with Hypothyroidism Secondary to Lingual Thyroid and Functional Characterization of the Mutant Receptor

We describe a rare case of congenital hypothyroidism and an extremely high serum thyrotropin (TSH) level caused by a combination of resistance to thyroid hormone (RTH) and a lingual thyroid. As the RTH mutant, R316C, was new, the optimum dose of levothyroxine was unclear. To aid in assessment of the therapy, we characterized the mutant R316C thyroid hormone receptor (TR) and compared it with a common mutant, R316H, using in vitro studies. The patient was a newborn female having severe hypothyroidism with a free thyroxine level of 0.36 ng/dL and a serum TSH level of 177 microU/mL. A scintiscan showed ectopic lingual thyroid tissue without a normal thyroid gland. Supplementation with levothyroxine at a dose of >350 microg/day did not normalize the serum TSH level; however, the patient showed normal growth and intelligence at 14 years of age. Consistent with the results of a computer analysis, the binding of R316C to triiodothyronine (T3) was significantly decreased to 38% that of the wild type. Electrophoretic mobility shift assay demonstrated that like R316H, R316C did not form a homodimer, but formed a heterodimer with RXR. However, a glutathione-S-transferase pull-down assay showed reduced binding of R316C with NCoR in the absence of T3 and impaired release in the presence of T3. In addition, transient transfection experiments demonstrated that unlike R316H, R316C had severe impairment of transcriptional activity on genes both positively and negatively regulated by thyroid hormone. It also had a clear dominant negative effect on genes negatively, but not positively, regulated by thyroid hormone, including the TSH-releasing hormone and TSHbeta genes. This is the first reported case of a R316C TR mutation. The characteristics of the R316C mutant differed from those of the R316H mutant. Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum TSH level with high dose of levothyroxine might be optimum for normal growth.

Inhibition of Thyroid Hormone Release from Cultured Amphibian Thyroid Glands by Methimazole, 6-Propylthiouracil, and Perchlorate

Thyroid gland explant cultures from prometamorphic Xenopus laevis tadpoles were evaluated for their utility in assessing chemicals for thyroid hormone (TH) synthesis disruption. The response of cultured thyroid glands to bovine thyroid stimulating hormone (bTSH) and the TH synthesis inhibitors methimazole, 6-propylthiouracil, and perchlorate was determined. Thyroid glands continuously exposed for 12 days to graded concentrations of bTSH released thyroxine (T4) in a dose-dependent manner. Over time, the glands appeared to reach a constant daily rate of T4 release. This suggested that the T4 stores in the glands were initially depleted but continuous release was maintained by synthesis of new hormone. The potency of methimazole, 6-propylthiouracil, and perchlorate for inhibiting T4 release was determined using glands cotreated with a single maximally effective bTSH concentration and graded concentrations of chemical. Inhibition of T4 release was dose dependent for all three chemicals. Perchlorate was the most potent inhibitor of T4 release. Methimazole and 6-propylthiouracil exhibited lower potency than perchlorate but similar potency to each other. The IC(50) (mean ± SD) for inhibition of T4 release by the thyroid glands was 1.2 ± 0.55, 8.6 ± 1.3, and 13 ± 4.0 μM for perchlorate, 6-propylthiouracil, and methimazole, respectively. This model system shows promise as a tool to evaluate the potency of chemicals that inhibit T4 release from thyroid glands and may be predictive of in vivo T4 synthesis inhibition in prometamorphic tadpoles.

Thyroidal thyroxine and triiodothyronine in autonomously functioning thyroid nodule and paranodular tissue.

Thyroidal thyroxine (T4), triiodothyronine (T3), thyroglobulin (Tg) and T4/T3 ratio were investigated in nodular and paranodular tissue from 16 patients with autonomously functioning thyroid adenomas. The concentration of T4 and T3 in the nodule were 97.7 +/- 20.5 (Mean +/- SE) and 10.2 +/- 2.4 micrograms/g wet weight (w.w.). Both iodothyronines were significantly lower in paranodular tissue (22.6 +/- 4.8 and 1.45 +/- 0.32 micrograms/g w.w., respectively), but with disproportionately decreased T3 which resulted in T4/T3 ratio (25.4 +/- 6.4) higher than in adenoma tissue (11.2 +/- 1.6). In patients with high normal or supranormal serum T3 concentration, thyroidal concentration of T3 in adenoma tissue was higher (15.6 +/- 5.0 vs. 6.3 +/- 1.2 micrograms/g w.w.) and T4/T3 ratio lower (8.05 +/- 2.1 vs. 13.2 +/- 1.9) than in patients with normal serum T3. The results suggest that thyroid release of T3 from adenoma is relatively higher than T4 in patients with autonomously functioning thyroid nodules and increased peripheral T3.

T3-release from autonomously functioning thyroid nodules in vitro.

Toxic thyroid nodules have been shown to be of clonal origin. In a portion of them, point mutations affecting either the gene of the TSH receptor (TSHr) or the alpha-subunit of stimulating G-protein, consecutively leading to enhanced cAMP levels, which may enhance growth or functional activity of the thyrocyte or both, were recently found. To complement these studies, we evaluated hormone response (i.e. T3 release) in vitro from tissues derived from toxic thyroid nodules as compared directly to the surrounding paranodular tissues as well as tissues derived from euthyroid goiter and from patients with Graves' disease. Experiments were conducted in the presence and absence of bTSH or Graves' immunoglobulines. Tissues obtained during surgery were incubated over 5 h, followed by equilibrium dialysis for 24 h, and determination of free T3 in an aliquot by RIA. Basal T3 release in nodular tissues (n = 10) was significantly higher (median: 7.3 ng/l) compared to paranodular tissues (3.2 ng/l; P < 0.01), tissues derived from euthyroid goiter (1.3 ng/l; n = 12; P < 0.001) and thyroid tissues derived from patients with Graves' disease (2.5 ng/l; n = 6; P < 0.001). Upon stimulation with bTSH (1 IU/l), median T3 concentrations markedly increased to 11.5 ng/l (P < 0.05), 7.3 ng/l (P < 0.05), 4.2 ng/l (P < 0.01) and 3.2 ng/l (P = N.S.), respectively. Stimulation over basal values was 1.6-fold in nodular tissues, 2.3-fold in paranodular tissues, 3.2-fold in euthyroid goiter and 1.3-fold in Graves' disease. In toxic thyroid nodules basal hormone-releasing activities were stimulated by fifteen out of twenty (75%) Graves' sera tested. For comparison, stimulation in other tissues occurred in 45% (paranodular), 80% (euthyroid goiter) and 35% (Graves' disease), respectively. In conclusion, tissue derived from toxic thyroid nodules exhibits enhanced basal hormone release as compared to both, the surrounding paranodular tissues and tissues from euthyroid goiter in vitro, which may reflect constitutional activation of TSHr, alpha-subunit of stimulating G-protein or other so far unknown intermediate by point mutations affecting the respective genes. Hyperactivities in toxic thyroid nodules may be even further enhanced by external stimulators such as TSH or TSH receptor antibodies. The first stimulator may have clinical relevance in patients with toxic thyroid nodules and not yet suppressed TSH; the latter could play a role in the rare Marine Lenhart syndrome.

Physiological variables of horses after road transport

In order to investigate the effects of short road transport stress on total and free iodothyronines, body weight (BW), rectal temperature and heart rate (HR) changes, 126 healthy stallions were studied in basal conditions, before and after transport. A total of 60 Thoroughbred and 66 crossbred stallions aged 4 to 15 years with previous travelling experience were transported by road in a commercial trailer for a period of about 3 to 4 h (distance under 300 km). Blood samples and functional variables were collected in each horse box, one week before loading and transport in basal conditions (control samples), one week later immediately before loading (pre-samples) and again after transport and unloading (about 3 to 4 h) in each new horse box, within 30 min of their arrival at the breeding stations (post-samples). Compared to the before-transport values, increases in circulating T3, T4 and fT4 levels (P < 0.01) were observed after transport, irrespective of breed, but not for fT3 levels. Lower T4 and fT4 levels were observed in basal II (at 1100 h) (P < 0.01) than in basal I (at 0800 h) conditions and before transport. Thoroughbreds showed higher fT3 (P < 0.05) and fT4 (P < 0.01) levels after transport than crossbred stallions. No significant differences were observed for T3 and T4. Compared to the before-transport values, significant increases in rectal temperature (P < 0.01) and HR (P < 0.05) were observed after transport. No differences were observed between basal I, II and before values for functional variables. Significant correlations between T3 and rectal temperature, BW and HR were found. The results indicate that short road transport induces a preferential release of T3, T4 and fT4 hormones from the thyroid gland in relation to different breed, and an increase in rectal temperature and HR. No significant changes in BW were observed. No differences were observed in relation to different ages. The data obtained suggest that the stallion’s thyroid hormones and functional variables may play an important role in assessing the effects of transport stress and a horse’s coping strategy.

The Neuroendocrine Effects of Traumatic Brain Injury

The Neuroendocrine Effects of Traumatic Brain Injury

The Neuroendocrine Effects of Traumatic Brain Injury

Neuroendocrine dysfunction after traumatic brain injury (TBI) is under-diagnosed, under-treated, and may adversely affect the rate of recovery. Single or multiple pituitary-target hormone disruption occurs in up to two-thirds of persons with TBI, most commonly affecting the gonadal and growth hormone axes. The time course of decline in and recovery of pituitary function in relation to cognitive dysfunction and rehabilitation progress are not well described. This article reviews the clinical spectrum of neuroendocrine deficits after TBI and their underlying mechanisms. Future studies of the effects of hormonal replacement on recovery are recommended.

Effects of chlortetracycline and Synovex-S® on growth rate and on plasma growth hormone and thyroid hormone concentrations following administration of thyrotropin-releasing hormone and GH-releasing hormone in beef steers

Twenty-four Angus steers (365 kg ± 4) were assigned randomly to a 2 × 2 factorial arrangement of treatments of either 0 or 350 mg chlortetracycline d-1, with or without Synovex-S to test the effects of chlortetracycline (CTC) and estrogenic implant on release of growth hormone (GH) and thyroid hormones. Steers received ad libitum a concentrate-forage diet over a 112-d feeding study, and growth and carcass characteristics were determined. On days 30, 56, and 106, steers received an injection, via jugular catheter, of 1.0 µg kg-1 BW thyrotropin-releasing hormone (TRH) + 0.1 µg kg-1 BW GH-releasing hormone (GHRH) and blood was collected from -30 to 360 min post-injection. Overall, compared with non-implanted steers, Synovex-S increased (P ≤ 0.009) rate and efficiency of gain, decreased (P = 0.05) time to peak for GH concentrations, whereas baseline concentrations of thyroid-stimulating hormone (TSH) were increased (P = 0.03). Additionally, the TSH response curve (P ≤ 0.05) and magnitude of triiodothyronine (T3; P = 0.01) response were greater following TRH + GHRH challenge for implanted versus nonimplanted steers. There were no main effects of CTC; however, CTC attenuated (P ≤ 0.05) the effects of implant on T3 release, slaughter weight, and carcass composition. In conclusion, Synovex-S alone increased BW gain and enhanced the response of GH, TSH, and T3 to a TRH + GHRH challenge, whereas CTC alone did not affect rate and composition of gain or release of pituitary and thyroid hormones. However, CTC appeared to mitigate the effects of implant on T3 release and carcass composition. Key words: Growth hormone, thyroid, estrogen, chlortetracycline, bovine, growth

Thyroid Hormone Synthesis and Secretion in Humans after 80 Milligrams of Iodine for 15 Days and Subsequent Withdrawal

In animals, acute iodine administration results in acute intrathyroidal inhibition of iodinations followed by escape of the inhibition if the excessive iodine intake continues. In humans, the intrathyroidal nonhormonal and hormonal iodine concentration after exposure to large doses of iodine for a relatively long period of time is not known. To determine whether, in human thyroid, administration of large doses of iodine for a relatively long time results in alterations of intrathyroidal hormonal (HI) T4 and T3 and total iodine (TI) content, as well as whether changes in serum concentration of thyroid hormones and TSH would occur after iodine administration or discontinuation. In 33 euthyroid patients with single thyroid nodule or hyperparathyroidism, Lugol solution (80 mg iodine) was administered for 15 d before operation. Groups of six to eight patients underwent operation 0, 5, 10, and 15 d after iodine withdrawal. TI, HI in a sample of thyroid tissue, and serum concentration of T4, T3, and TSH were measured. In 21 normal euthyroid subjects who did not undergo operation, a similar protocol was used and serial blood measurements were taken. Intrathyroidal TI, HI, and serum thyroid hormone and TSH measurements were the main outcome measure. Intrathyroidal HI content and serum T4 and T3 were unchanged during and after iodine discontinuation. TI was increased during iodine administration and returned to control values 5 d after discontinuation of iodine. The ratio of HI/TI was decreased and returned to control values 15 d after the iodine was discontinued. Serum TSH was increased during iodine administration and returned to control values 10 d after iodine withdrawal. In humans, administration of iodine for a relatively long period of time was accompanied by increased intrathyroidal TI, but no changes in HI or demonstrable increases of serum T4 and T3 were observed. It is hypothesized that the maintenance of normal intrathyroidal HI is the result of the combined inhibitory effect of iodine on thyroid hormone synthesis and on the release of T4 and T3 from the thyroid.

Localization and role of leptin in the thyroid gland of the lizardPodarcis sicula (reptilia, lacertidae)

Leptin, the product of the ob gene, is a hormone secreted by adipocytes that regulates food intake and energy expenditure. The hypothalamus-pituitary-thyroid axis is markedly influenced by the metabolism status, being suppressed during food deprivation. The present study was designed to ascertain whether (1) lizard thyroid gland expresses the long form of leptin receptor (Ob-Rb) and (2) the leptin administration affects the thyroid gland activity in this species (and to verify whether leptin plays a similar role in reptiles as observed in the other vertebrates). The presence of leptin receptor in the thyroid gland of Podarcis sicula was demonstrated by immunohistochemical technique (avidin-biotin-peroxidase complex--ABC method). The role of leptin in the control of thyroid gland activity was studied in vivo using light microscopy (LM) technique coupled to a specific radioimmunoassay for thyroid-stimulating hormone (TSH) and thyroid hormones (T4 and T3). Leptin (0.1 mg/100 g body wt)/day increased T4 and T3 release for 3 days but decreased the plasma concentration of TSH; using LM clear signs of stimulation in the thyroid gland were observed. These findings suggest that systemic administration of leptin stimulates the morphophysiology of the thyroid gland in the lizard through a direct mechanism involving Ob-Rb.

Underestimates and Overestimates of Total Thyroxine Concentrations Caused by Unwanted Thyroxine-Binding Protein Effects

The first evidence of unwanted serum protein effects on analogue-based total thyroxine (T4) determinations came from a study that varied serum protein concentrations while total T4 concentrations were constant. The present study approached this issue by varying total T4 concentrations while protein concentrations were constant. Four analogue-based total T4 immunoassays were applied to solutions that contained either free T4 without binding protein, a T4-binding protein without T4, or protein-bound T4. When total T4 concentrations were 3-12 microg/dL, the assays reported total T4 determinations that ranged from none detected to 23 microg/dL. These T4 determinations reflected the protein to which T4 was bound, in addition to the level of T4. Total T4 was underrepresented when T4 was unbound, or thyroxine-binding globulin (TBG) bound. Total T4 was overrepresented when T4 was albumin-bound, or transthyretin-bound. There were substantial disparities among assays applied to the same total T4 solutions. These assays reported no detectable T4 when applied to T4-binding protein solutions without protein-bound T4. Nonetheless, T4-binding proteins contributed to the underestimates and overestimates of protein bound T4. Different forms of protein bound T4 were quantified differently, evidence that protein-T4 complexes persist during quantification. We attribute the unexpected total T4 values to a combination of incomplete protein-bound T4 release from T4-binding proteins during quantification, and variably inaccurate quantifications of the protein-bound T4 that remained.

Involvement of Gonadotropin-Releasing Hormone in Thyroxine Release in Three different forms of Teleost Fish: Barfin Founder, Masu Salmon and Goldfish

Effects of gonadotropin-releasing hormone (GnRH) on thyroxine (T4) release in vivo and in vitro were studied in barfin flounder Verasper moseri, masu salmon Oncorhynchus masou and goldfish Carassius auratus. Seabream GnRH (sbGnRH) at a dose of 200 ng/50 g body weight (BW) significantly increased plasma T4 levels 1 h after the in vivo injection in the barfin flounder, but thereafter the levels normalized. Salmon GnRH (sGnRH) significantly increased plasma T4 levels l h after the injection with a significant return to initial levels in male masu salmon and male goldfish. In contrast, sGnRH and cGnRH-II in barfin flounder, and cGnRH-II in male masu salmon and male goldfish were not effective in stimulating T4 release. To clarify direct involvement of GnRH in T4 release, dissected lower jaw including scattered thyroid follicles was incubated with sbGnRH (1 µg/well) in barfin flounder, and with two doses (0.1 and 1 µg/well) of sGnRH in masu salmon and goldfish in vitro. T4 concentrations of control were stable during 24 h. Incubation of lower jaw with high dose (1 µg/well) of GnRH significantly (P<0.05) increased T4 concentrations of incubation medium at 1 h in all experimental fishes. These results indicate that direct stimulation of T4 secretion by GnRH occurs widely in teleost fish.